GlassScriptPhysician profile
Corin A Pesci
NPI 1013013762
$5,017.76
in general payments reported to CMS, 2019-2025
21 companies · $1,007 in 2025
The $1,007 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $555 · 2023: $717 · 2024: $2,739 · 2025: $1,007.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,264 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,263.64 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $741.25 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $727.66 | 2022-2025 | Ilumya, Absorica Ld, Winlevi |
| E.R. Squibb & Sons, L.L.C. | $536.64 | 2022-2025 | Sotyktu |
| Amgen INC. | $474.04 | 2022-2025 | Otezla, Otezla |
| Lilly USA, LLC | $425.50 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $392.74 | 2023-2025 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $298.08 | 2023-2025 | Zoryve |
| Janssen Biotech, INC. | $273.24 | 2022-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $195.51 | 2022-2025 | Dupixent |
| Genzyme Corporation | $185.16 | 2024 | |
| Novartis Pharmaceuticals Corporation | $156.13 | 2022-2024 | |
| Incyte Corporation | $149.87 | 2022-2024 | Opzelura |
| Leo Pharma INC. | $134.77 | 2024 | Adbry |
| Dermavant Sciences, INC. | $101.37 | 2022-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $47.35 | 2024-2025 | Cabtreo |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $40.66 | 2023 | |
| Organogenesis INC. | $39.44 | 2025 | Apligraf |
| Galderma Laboratories, L.P. | $33.09 | 2024 | |
| Pfizer INC. | $28.34 | 2024 | |
| Organon LLC | $21.46 | 2025 | Vtama |
| Verrica Pharmaceuticals INC. | $15.46 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corin Pesci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.